Afatinib (BIBW2992)

Name: Afatinib (BIBW2992)
Brand: Selleck Chemicals
SKU: S1011
Rating: 5 (201 reviews)

For research use only.

Catalog No.S1011

201 publications

Molecular Weight(MW): 485.94

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.

Selleck's Afatinib (BIBW2992) has been cited by 201 publications

Nature, 2019, 571(7763):127-131

PubMed: 31243371 ( click the link to review the publication )

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(5):638-646

PubMed: 29686424 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nat Med, 2017, 23(10):1167-1175

PubMed: 28920960 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2013, 3(2):168-81

PubMed: 23229345 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Oncogene, 2020, 39(20):3997-4013

PubMed: 32242147 ( click the link to review the publication )

Cancer Lett, 2020, 476:23-33

PubMed: 31958486 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cell Death Dis, 2020, 2;11(1):6

PubMed: 31919341 ( click the link to review the publication )

Cancer Discov, 2020, 10(5):674-687

PubMed: 32213539 ( click the link to review the publication )
Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):129

PubMed: 32066410 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(3):605-619

PubMed: 32036454 ( click the link to review the publication )

Am J Transl Res, 2020, 15;12(3):847-856 eCollection 2020

PubMed: 32269717 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Radiat Oncol, 2020, 15(1):58

PubMed: 32143669 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

J Cancer, 2020, 11(1):241-250

PubMed: 31892990 ( click the link to review the publication )

Neurooncol Adv, 2020, Dec;2(1):vdaa020

PubMed: 32226941 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Oncogene, 2019, 38(30):5890-5904

PubMed: 31253872 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):266

PubMed: 31215502 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)

PubMed: 31181806 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Br J Cancer, 2019, 121(10):846-856

PubMed: 31607750 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )
Mol Cancer Ther, 2019, 18(4):733-742

PubMed: 30787176 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):920-928

PubMed: 30872380 ( click the link to review the publication )

J Cancer, 2019, 10(9):2063-2073

PubMed: 31205567 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(6):1282-1292

PubMed: 31285959 ( click the link to review the publication )

Oncogenesis, 2019, 8(10):54

PubMed: 31570699 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(11):2233-2243

PubMed: 31467113 ( click the link to review the publication )

Gynecol Oncol, 2019, 153(1):158-164

PubMed: 30630630 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28881

PubMed: 31152452 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0248-2

PubMed: 31171828 ( click the link to review the publication )

Front Physiol, 2019, 10:189

PubMed: 30971932 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Transl Oncol, 2019, 12(6):852-858

PubMed: 31030101 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1059-1066

PubMed: 30483795 ( click the link to review the publication )

Clin Otolaryngol, 2019, 10.1111/coa.13434

PubMed: 31536667 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3317-3325

PubMed: 31432165 ( click the link to review the publication )

Pharmaceuticals (Basel), 2019, 12(4)

PubMed: 31703435 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )
Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Nat Struct Mol Biol, 2018, 25(6):454-462

PubMed: 29760531 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(11):2594-2604

PubMed: 29298799 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Immunol Res, 2018, 6(12):1511-1523

PubMed: 30242021 ( click the link to review the publication )

Theranostics, 2018, 8(12):3176-3188

PubMed: 29930721 ( click the link to review the publication )

Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

Cancer Discov, 2018, 8(9):1087-1095

PubMed: 29802158 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1648-1658

PubMed: 29748209 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2144-2155

PubMed: 30065098 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):830-854

PubMed: 29603584 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):441-462

PubMed: 29325228 ( click the link to review the publication )

Cancer Sci, 2018, 109(11):3657-3661

PubMed: 30255614 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Front Oncol, 2018, 8:432

PubMed: 30345256 ( click the link to review the publication )
Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(42):16518-16527

PubMed: 30166343 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

Ann Thorac Surg, 2018, 105(2):363-370

PubMed: 29223420 ( click the link to review the publication )

Int J Oncol, 2018, 53(4):1544-1556

PubMed: 30066854 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Biosci Rep, 2018, 38(6)

PubMed: 30420490 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8201-8209

PubMed: 30568455 ( click the link to review the publication )

J Craniomaxillofac Surg, 2018, 46(3):492-497

PubMed: 29311018 ( click the link to review the publication )

Bladder Cancer, 2018, 4(1):77-90

PubMed: 29430509 ( click the link to review the publication )

J Am Chem Soc, 2018, 140(40):12785-12797

PubMed: 30256630 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Oncogene, 2017, 36(13):1873-1886

PubMed: 27694893 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Cell Death Dis, 2017, 8(5):e2773

PubMed: 28492539 ( click the link to review the publication )

Neoplasia, 2017, 19(12):1012-1021

PubMed: 29136529 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )
Cancer Prev Res, 2017, 10(1):76-88

PubMed: 27756753 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 335:16-27

PubMed: 28942004 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(3):656-661

PubMed: 28756224 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

BMB Rep, 2017, 50(3):150-155

PubMed: 28256196 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28145866 ( click the link to review the publication )

Gut, 2016, 1296-305

PubMed: 26001389 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(1):133-41

PubMed: 26371512 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(8):1708-19

PubMed: 27648360 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146311

PubMed: 26735495 ( click the link to review the publication )

Mol Med Rep, 2016, 13(3):2338-44

PubMed: 26782932 ( click the link to review the publication )

Oncotarget, 2016, 7(28):42859-42872

PubMed: 27374095 ( click the link to review the publication )
Oncotarget, 2016, 7(36):58038-58050

PubMed: 27487128 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Gut, 2015, 10.1136/gutjnl-2014-309026

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(1):93-101

PubMed: 25384171 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4597-606

PubMed: 26138066 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(3):375-84

PubMed: ( click the link to review the publication )

Cell Tissue Res, 2015, 359(3):799-816

PubMed: ( click the link to review the publication )

Oncol Rep, 2015, 34(6):2864-70

PubMed: 26503698 ( click the link to review the publication )

Oncol Rep, 2015, 34(6):2864-70

PubMed: 26503698 ( click the link to review the publication )

Arch Immunol Ther Exp, 2015, 10.1007/s00005-015-0330-5

PubMed: 25678473 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123623

PubMed: 25853726 ( click the link to review the publication )

Anticancer Res, 2015, 35(4):2005-8

PubMed: 25862853 ( click the link to review the publication )

J Anal Methods Chem, 2015, 2015:215128

PubMed: 26101692 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )
Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5423-34

PubMed: 25189483 ( click the link to review the publication )

Cancer Res, 2014, 74(1):341-52

PubMed: 24177178 ( click the link to review the publication )

Oncogene, 2014, 33(25):3334-41

PubMed: 23873022 ( click the link to review the publication )

Anal Chem, 2014, 86(21):10568-75

PubMed: 25263480 ( click the link to review the publication )

Br J Cancer, 2014, 111(9):1750-6

PubMed: 25268372 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(9):1239-47

PubMed: 24971884 ( click the link to review the publication )

Histochem Cell Biol, 2014, 142(4):361-71

PubMed: 24824474 ( click the link to review the publication )

Target Oncol, 2014, 10.1007/s11523-014-0344-7

PubMed: 25341405 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Drug Metab Lett, 2014, 8(1):19-30

PubMed: 24628405 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12877-90

PubMed: 25375092 ( click the link to review the publication )

Drug Metab Lett, 2014, 8(1):19-30

PubMed: 24628405 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

Sci Transl Med, 2013, 5(199):199ra111

PubMed: 23966300 ( click the link to review the publication )

Eur J Cancer, 2013, 49(6):1458-66

PubMed: 23153706 ( click the link to review the publication )

Oncogene, 2013, 32(37):4427-35

PubMed: 23045273 ( click the link to review the publication )

Cancer Sci, 2013, 104(5):584-9

PubMed: 23387505 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(6):537-45

PubMed: 23760496 ( click the link to review the publication )
PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(6):1663-71

PubMed: 22317763 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41017

PubMed: 22815900 ( click the link to review the publication )

Oncol Res, 2011, 19(10-11):471-8

PubMed: 22715590 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Targets

EGFR (L858R) ^[1] (Cell-free assay)	EGFR (wt) ^[1] (Cell-free assay)	ErbB4 ^[2] (Cell-free assay)	EGFR (L858R/T790M) ^[1] (Cell-free assay)	HER2 ^[1] (Cell-free assay)
0.4 nM	0.5 nM	1 nM	10 nM	14 nM

In vitro

BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HDLM-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEX3TFNKSzVyPUCuNFA2PzJizszN	NF3LTotUSU6JRWK=
KASUMI-1	NH7qXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwMEC5NVEh\|ryP	NF;KfVJUSU6JRWK=
HCC2218	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUiw[2NEUUN3ME2wMlAxQTh5IN88US=>	MUPTRW5ITVJ?
KARPAS-45	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMEG2O\|Eh\|ryP	M1G5XXNCVkeHUh?=
HSC-4	M3zV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHnXItFUUN3ME2wMlAyPzR6IN88US=>	NHLF[\|FUSU6JRWK=
CHL-1	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3ZTpJFUUN3ME2wMlAyQDN7IN88US=>	MX7TRW5ITVJ?
KY821	NYrUXIRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMEKwOkDPxE1?	MlPGV2FPT0WU
NCI-N87	MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTmTWM2OD1yLkCyO\|c{KM7:TR?=	MWXTRW5ITVJ?
DOK	MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PIXmlEPTB;MD6wN\|E6PCEQvF2=	MUXTRW5ITVJ?
DSH1	MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwMEOzNVQh\|ryP	NVTodZZRW0GQR1XS
MDA-MB-175-VII	M134bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlG4TWM2OD1yLkCzOFE3KM7:TR?=	MlG1V2FPT0WU
NCI-H2170	NXLDdndLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnGRYg6UUN3ME2wMlA{PzJ6IN88US=>	NIfNXIJUSU6JRWK=
BT-474	MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMES5PFYh\|ryP	MYXTRW5ITVJ?
EFO-27	NW\Ge4FNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mme4TWM2OD1yLkC1NVgzKM7:TR?=	NYHqTY1VW0GQR1XS
NCI-H720	Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;sOGI4UUN3ME2wMlA2OzJ3IN88US=>	NGrYZlhUSU6JRWK=
PC-14	NV;I[VBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTBwMEW2Olgh\|ryP	M2OyZnNCVkeHUh?=
EC-GI-10	NVXa[opRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEG2[lJKSzVyPUCuNFU6OTJizszN	M4XSbHNCVkeHUh?=
KYSE-450	NFnwWoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXZeo5rUUN3ME2wMlA2QTd6IN88US=>	NUnBW4FkW0GQR1XS
BPH-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfJVXJuUUN3ME2wMlA2QTh6IN88US=>	NHvvRZhUSU6JRWK=
NCI-H292	M37nZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVyxXXg3UUN3ME2wMlA3ODlizszN	M{DNdXNCVkeHUh?=
H9	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrIbXpzUUN3ME2wMlA4OTN{IN88US=>	M1TGSnNCVkeHUh?=
NCI-H526	MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vxTWlEPTB;MD6wO\|gzOyEQvF2=	NHm5bZZUSU6JRWK=
NCI-H1623	NUe5SppuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYP4cJkzUUN3ME2wMlA5ODJ3IN88US=>	MUXTRW5ITVJ?
KYSE-140	NIfzN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwMEizN{DPxE1?	NVLsfVF1W0GQR1XS
Ca9-22	Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEWxSodKSzVyPUCuNFg{PTNizszN	NFvMS\|NUSU6JRWK=
AU565	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4H3S2lEPTB;MD6wPFUxPCEQvF2=	MXjTRW5ITVJ?
ZR-75-30	NWTyPJA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwMEm1OFUh\|ryP	NUfqcldVW0GQR1XS
NCI-H1770	MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnOwTWM2OD1yLkGwNlgh\|ryP	NUHPcIkxW0GQR1XS
LB2241-RCC	NIjsSYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2npVmlEPTB;MD6xNFg5PCEQvF2=	NIfWVoxUSU6JRWK=
CAL-39	M3PqNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTkTWM2OD1yLkGxO\|kzKM7:TR?=	Mn;LV2FPT0WU
UACC-893	NETXVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwMUG4PFUh\|ryP	Mn3SV2FPT0WU
LU-65	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;kW\|NKSzVyPUCuNVI3OzNizszN	MkHZV2FPT0WU
HN	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHMTWM2OD1yLkGzNFc4KM7:TR?=	MmLBV2FPT0WU
TI-73	M3;GVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX60[JVRUUN3ME2wMlE1PzF3IN88US=>	M4HxenNCVkeHUh?=
KU812	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3wTWM2OD1yLkG1OFU3KM7:TR?=	MmrwV2FPT0WU
SW13	NGH6[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml74TWM2OD1yLkG2NlE3KM7:TR?=	NHHJ[\|NUSU6JRWK=
BB30-HNC	NHXEdYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\XN4hKSzVyPUCuNVY2PzZizszN	MUjTRW5ITVJ?
HSC-2	MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknBTWM2OD1yLkG2PFM4KM7:TR?=	MWrTRW5ITVJ?
BV-173	NUP2VVFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\iTWM2OD1yLkG3OVk3KM7:TR?=	MknPV2FPT0WU
CAL-27	M2TpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPiS3F{UUN3ME2wMlE4PjN4IN88US=>	NF;zSJpUSU6JRWK=
SBC-1	M{\vXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk[wTWM2OD1yLkG4PVU6KM7:TR?=	M3ewbXNCVkeHUh?=
CAL-33	NVLvVGU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\KeHlMUUN3ME2wMlIxOTh2IN88US=>	MV\TRW5ITVJ?
NCI-H209	NWHwcJhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTOTWM2OD1yLkKwOFYh\|ryP	MnPDV2FPT0WU
COR-L105	NYLYNVhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHXTWM2OD1yLkKxNFg1KM7:TR?=	MkLqV2FPT0WU
HSC-3	NWL0NItsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHCTWM2OD1yLkKxNVk5KM7:TR?=	NF[wdZVUSU6JRWK=
NCI-H69	M4X3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnobJhyUUN3ME2wMlIyPDVzIN88US=>	M2LxOXNCVkeHUh?=
MOLT-13	NX3ZUoVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwMkO5O\|Uh\|ryP	M{nucHNCVkeHUh?=
ML-2	NXKxboNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTzTWM2OD1yLkK0PFAzKM7:TR?=	Mn3PV2FPT0WU
IGROV-1	M1jWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk[0TWM2OD1yLkK1PVUzKM7:TR?=	MknXV2FPT0WU
TK10	NYryUo9mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMk[3N\|gh\|ryP	M4OyUXNCVkeHUh?=
EoL-1-cell	NFzPSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M16yeGlEPTB;MD6yOlg6OiEQvF2=	NXXwUJZ6W0GQR1XS
HO-1-N-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLTTWM2OD1yLkK3PFU{KM7:TR?=	M2PUXnNCVkeHUh?=
BHY	MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPITWM2OD1yLkK4OlU2KM7:TR?=	Ml7ZV2FPT0WU
LU-139	NWDJcnZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHz[JZCUUN3ME2wMlMxPTFizszN	M{HHcHNCVkeHUh?=
23132-87	MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHz6Z4NKSzVyPUCuN\|E6OjNizszN	MmXFV2FPT0WU
ACHN	NF\xSHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXX2dIxKUUN3ME2wMlMyQTl2IN88US=>	M{HQPXNCVkeHUh?=
DoTc2-4510	MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnFUlBKSzVyPUCuN\|IzOTlizszN	MVvTRW5ITVJ?
BB65-RCC	NIewVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrPZ3k{UUN3ME2wMlM1PTl\|IN88US=>	MVXTRW5ITVJ?
HLE	MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwM{WwOFYh\|ryP	NWTDb5VmW0GQR1XS
HCC1419	NHmwWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHL2TphKSzVyPUCuN\|Y1ODhizszN	NYPac2NOW0GQR1XS
A388	MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkK3TWM2OD1yLkO2PFU4KM7:TR?=	NYPpc25RW0GQR1XS
NUGC-3	MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jOUWlEPTB;MD6zPFM4OyEQvF2=	NV7QeZc5W0GQR1XS
KYSE-180	NFS1SIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TZNWlEPTB;MD6zPVA5QSEQvF2=	NHns[ItUSU6JRWK=
TE-6	NH:0eZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXz3UJNIUUN3ME2wMlQxOjR4IN88US=>	NWKxTnRVW0GQR1XS
A498	Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn30TWM2OD1yLkSwOlc1KM7:TR?=	M3j5fHNCVkeHUh?=
NCI-H1648	Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwNESxPFIh\|ryP	NV61Now4W0GQR1XS
DU-145	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\qW5RKSzVyPUCuOFQ5OzNizszN	NWLvdGt5W0GQR1XS
CW-2	NYK1OHJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3j3b2lEPTB;MD60OlkyPCEQvF2=	MonpV2FPT0WU
A431	MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjjXIVlUUN3ME2wMlQ5OjN\|IN88US=>	MWfTRW5ITVJ?
SAS	NWnydHJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;3ZVhKSzVyPUCuOFg{QThizszN	NF;HVZpUSU6JRWK=
NCI-H2126	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;iSZhKSzVyPUCuOVE6OjZizszN	M1vWWXNCVkeHUh?=
NCI-H358	NHPvZ\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH6zWHRKSzVyPUCuOVMzOSEQvF2=	NG\0ToVUSU6JRWK=
FADU	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmm2TWM2OD1yLkW0OFA1KM7:TR?=	MWHTRW5ITVJ?
ACN	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHqx[m5KSzVyPUCuOVUxQTRizszN	Ml3kV2FPT0WU
HCC70	MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXwepNNUUN3ME2wMlU4PjZzIN88US=>	NUPXU2pPW0GQR1XS
NCI-H1838	M{TGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\iUoxKSzVyPUCuOlAzQTlizszN	NH62cmVUSU6JRWK=
CAL-54	M1:zXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfyTYhoUUN3ME2wMlYyPjJzIN88US=>	MWfTRW5ITVJ?
NCI-H1975	MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHVc4N7UUN3ME2wMlYyPzJ6IN88US=>	NVfOW5JKW0GQR1XS
COR-L88	NE\mWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnveFVqUUN3ME2wMlY1OTF\|IN88US=>	NFKxTHRUSU6JRWK=
CTV-1	NFGxSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LIbmlEPTB;MD62OFM6OiEQvF2=	MlXYV2FPT0WU
EW-18	NHLuVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwNki2PVgh\|ryP	NFT2OY1USU6JRWK=
HCC1806	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwNkm2OlYh\|ryP	NVHkdGQyW0GQR1XS
HuP-T4	NVHt[ItJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnP1TWM2OD1yLk[5O\|Yh\|ryP	NXLQNIFiW0GQR1XS
MDA-MB-361	MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITnToZKSzVyPUCuO\|I3PjJizszN	MnPHV2FPT0WU
NCI-H1573	MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXe2UFVFUUN3ME2wMlc{PjNizszN	M4XFXXNCVkeHUh?=
KU-19-19	NIXFc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrnWHVKSzVyPUCuO\|c1PjRizszN	NYfNRXVJW0GQR1XS
COLO-678	NFjSU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4S5eGlEPTB;MD64NFg{PCEQvF2=	NH3MRnRUSU6JRWK=
C-33-A	NXXsNHdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorYTWM2OD1yLkixNlk4KM7:TR?=	NUXYd2JFW0GQR1XS
Calu-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XXR2lEPTB;MD64NVQ{PCEQvF2=	NFPKfZJUSU6JRWK=
AGS	MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPmd\|I5UUN3ME2wMlg{PjR6IN88US=>	NWHDZot2W0GQR1XS
SCC-25	NIjWb\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLXb29bUUN3ME2wMlg1OTdzIN88US=>	NFvZdGJUSU6JRWK=
JVM-2	NYj6R4dTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHhT4tKSzVyPUCuPFgzQTlizszN	M4nabnNCVkeHUh?=
HCE-T	M3z1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPqfoZKSzVyPUCuPFg1OjhizszN	NX\1TY5TW0GQR1XS
ES4	NUfxO4s2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfQTWM2OD1yLkm3PFM3KM7:TR?=	MoDyV2FPT0WU
EKVX	M1yxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfTO4FKSzVyPUGuNFExPjRizszN	MnP0V2FPT0WU
D-542MG	NV:3RZEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDnR2xyUUN3ME2xMlAyODZ2IN88US=>	Moj6V2FPT0WU
SW1116	NWf0bWNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTFwMEGyPFch\|ryP	NGCwWFhUSU6JRWK=
5637	NWDadY41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjuO215UUN3ME2xMlAyPTFizszN	MX;TRW5ITVJ?
HT-1376	NV\GRWdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\td\|BKSzVyPUGuNFE2OTNizszN	M4i0XXNCVkeHUh?=
NB69	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPkWJJKSzVyPUGuNFI6PDVizszN	M13J[nNCVkeHUh?=
YKG-1	MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjH[JpSUUN3ME2xMlA2PDF7IN88US=>	MVPTRW5ITVJ?
EW-3	NEHidZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnzTIFKUUN3ME2xMlA4QDh\|IN88US=>	M{PQNnNCVkeHUh?=
GCIY	NVy3PFJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jFTGlEPTB;MT6wPFExPCEQvF2=	M{DZWXNCVkeHUh?=
SK-MES-1	NG\ucYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHxTWM2OD1zLkGxOFg4KM7:TR?=	M{TsZ3NCVkeHUh?=
PANC-08-13	NV;FNYdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoL6TWM2OD1zLkG2OFE3KM7:TR?=	NF\ueFRUSU6JRWK=
SK-NEP-1	NFfRWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nGSWlEPTB;MT6xO\|UyOyEQvF2=	NHyxfYhUSU6JRWK=
SW954	NHP2cXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrHNXJRUUN3ME2xMlIxOjF2IN88US=>	NVvBbnpZW0GQR1XS
NCI-SNU-5	NFPjOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTFwMkO5JO69VQ>?	MmTSV2FPT0WU
SW48	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfHTWM2OD1zLkK1OFMzKM7:TR?=	MVPTRW5ITVJ?
HT-3	NGm1V3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTFwMki3OVMh\|ryP	NIfKT21USU6JRWK=
ETK-1	NVHscFNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmn6TWM2OD1zLkO3OFU3KM7:TR?=	M{\FR3NCVkeHUh?=
SCC-15	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zGdGlEPTB;MT6zPVQ2OSEQvF2=	M1;JZnNCVkeHUh?=
DU-4475	MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYizcFNrUUN3ME2xMlQxOTJzIN88US=>	NFr5eFJUSU6JRWK=
NB5	M1iwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHWzTZJKSzVyPUGuOFE{OTdizszN	NVjWb\|RlW0GQR1XS
CFPAC-1	M4nVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\ZTWM2OD1zLkSyOFk{KM7:TR?=	M{CyWXNCVkeHUh?=
NCI-H630	NYfNd\|FLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nmNmlEPTB;MT60OVU5OiEQvF2=	Mn;mV2FPT0WU
NCI-H82	M17TfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTFwNUSwNFYh\|ryP	MkDlV2FPT0WU
ECC10	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTFwNUWzOlkh\|ryP	M1rsRnNCVkeHUh?=
K5	NH3OT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTFwNUizOVch\|ryP	MX;TRW5ITVJ?
ME-180	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnURmRKSzVyPUGuOlExQTZizszN	NGnHNGJUSU6JRWK=
KYSE-410	NILLTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTFwNkW2O\|Ih\|ryP	NV3jeWk5W0GQR1XS
G-401	NFnm[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7LUoVKSzVyPUGuOlc1OTNizszN	MUPTRW5ITVJ?
TGBC24TKB	M3zucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2K1S2lEPTB;MT62PFI{KM7:TR?=	M133NHNCVkeHUh?=
Detroit562	NHjr[\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTFwN{CxOVIh\|ryP	MoTGV2FPT0WU
OE19	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTHTWM2OD1zLkexOVEzKM7:TR?=	M2\IdXNCVkeHUh?=
CAKI-1	M3y0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XVbWlEPTB;MT63PFIyOSEQvF2=	MknWV2FPT0WU
TE-12	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVuwfnBQUUN3ME2xMlgxPDF2IN88US=>	NELqOZdUSU6JRWK=
NCI-H1666	NVrFUoY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;ZbXRKSzVyPUGuPFA6PDhizszN	MlLwV2FPT0WU
TE-1	NX[zT2I3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;zRWlEPTB;MT64NVQ4PSEQvF2=	MmK0V2FPT0WU
CAL-12T	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofCTWM2OD1zLki4PVQ2KM7:TR?=	NH;Ne21USU6JRWK=
TE-8	NEnLXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTFwOUGzO\|ch\|ryP	Ml7XV2FPT0WU
KYSE-270	NUO2S5lQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrGVpFKSzVyPUKuNFI4OzJizszN	MWXTRW5ITVJ?
GMS-10	Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPTTWM2OD1{LkCzOVE4KM7:TR?=	M13LUHNCVkeHUh?=
A2780	MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULwWYY2UUN3ME2yMlA3Ojl2IN88US=>	M2L4VXNCVkeHUh?=
OMC-1	NU\ZTJRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4CzR2lEPTB;Mj6wPFE3QSEQvF2=	NYD1NY41W0GQR1XS
LoVo	M{LKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTJwMUC3PVch\|ryP	MXzTRW5ITVJ?
PANC-03-27	MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTJwMU[2N\|Eh\|ryP	MkDaV2FPT0WU
MDA-MB-157	MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrJRpNKSzVyPUKuNlE5OjhizszN	MYDTRW5ITVJ?
CaR-1	NX3zfFJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPj[GxKSzVyPUKuNlgzQDFizszN	M{XrSXNCVkeHUh?=
769-P	NUjHOoU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILBXlFKSzVyPUKuNlkxOzdizszN	Ml74V2FPT0WU
NB7	NX3lPYZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUm5W29wUUN3ME2yMlI6Pjd4IN88US=>	NID5NVZUSU6JRWK=
MKN7	MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\kTGlEPTB;Mj6zOVM{PSEQvF2=	NWHyZox1W0GQR1XS
NCI-H1048	M3H1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjxTWM2OD1{LkS5NVU5KM7:TR?=	NYnOTFBQW0GQR1XS
RCM-1	M33hU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfpdFNKSzVyPUKuOVI6OzhizszN	MXXTRW5ITVJ?
HT55	M2XEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlz2TWM2OD1{LkW3N\|gh\|ryP	MWHTRW5ITVJ?
HCC1569	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\RV29KSzVyPUKuOVgzQTdizszN	MX7TRW5ITVJ?
LXF-289	NEHHOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\xTWM2OD1{Lk[zOVY2KM7:TR?=	NH76[3FUSU6JRWK=
OVCAR-3	MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFThXphKSzVyPUKuOlcyPjdizszN	MVvTRW5ITVJ?
TE-10	NFjUclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWT1R453UUN3ME2yMlY5ODd6IN88US=>	MX;TRW5ITVJ?
SNU-C2B	M2\FdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzjTWM2OD1{Lk[4OlE3KM7:TR?=	MXnTRW5ITVJ?
LB1047-RCC	NWm2R3YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHZTWM2OD1{Lke0PFg5KM7:TR?=	NXvGOXlTW0GQR1XS
SN12C	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;GTWM2OD1{LkmxPVY1KM7:TR?=	NIHQNmNUSU6JRWK=
786-0	NIWwfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDjO3lVUUN3ME2zMlA3PDB6IN88US=>	MliwV2FPT0WU
HT-29	MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnrTWM2OD1\|LkC3N\|A6KM7:TR?=	NHnBZY5USU6JRWK=
RPMI-7951	M4nMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LVXWlEPTB;Mz6wO\|U6KM7:TR?=	MUHTRW5ITVJ?
NBsusSR	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkC5TWM2OD1\|LkG4NlU1KM7:TR?=	MYDTRW5ITVJ?
NKM-1	M3XVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVq5bGpGUUN3ME2zMlE5PzR2IN88US=>	M4LJVHNCVkeHUh?=
Capan-2	NIPUVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTNwNE[4O\|Uh\|ryP	MlvEV2FPT0WU
MKN1	NUjXO4VlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTNwNEexNFgh\|ryP	MmnvV2FPT0WU
OAW-42	MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTGTWM2OD1\|LkWwNFI3KM7:TR?=	NFzobpRUSU6JRWK=
SKG-IIIa	MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7nZnJnUUN3ME2zMlUzOjN5IN88US=>	NYDkU\|dUW0GQR1XS
no-11	NILoR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTNwNUO1OlQh\|ryP	NWe3VWhIW0GQR1XS
NY	NFu0[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTNwNUO2OVUh\|ryP	NV\P[npUW0GQR1XS
HEC-1	MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELuToxKSzVyPUOuOVg6PSEQvF2=	MXfTRW5ITVJ?
NCI-H441	MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HyR2lEPTB;Mz61PVg1OSEQvF2=	MoXOV2FPT0WU
NCI-H2009	NWe0NIJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXmTWM2OD1\|Lk[xNlE3KM7:TR?=	NFHkbopUSU6JRWK=
T47D	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTNwNkKyNVch\|ryP	MnzTV2FPT0WU
SNU-449	MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLFTWM2OD1\|Lk[1PFI3KM7:TR?=	MVrTRW5ITVJ?
NCI-SNU-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVz0[2FJUUN3ME2zMlY6PzN3IN88US=>	NITqZWNUSU6JRWK=
BT-20	M1vqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILvUmtKSzVyPUOuOlk4QTVizszN	NEXxfXRUSU6JRWK=
LS-123	NXWyOIpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHT1OpVKSzVyPUOuO\|QzQDRizszN	NEDoXGdUSU6JRWK=
8305C	NHrQcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrpTWM2OD1\|Lke1PVEyKM7:TR?=	NFzJemlUSU6JRWK=
OCUB-M	M1rX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTNwN{[xPFch\|ryP	NFvFXlZUSU6JRWK=
KOSC-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrNW2lGUUN3ME2zMlg{PDVzIN88US=>	NVPYWZVuW0GQR1XS
NCI-H1693	MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWOyc\|A3UUN3ME2zMlg1OThzIN88US=>	NYS4OGNxW0GQR1XS
TE-9	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfGSXJKSzVyPUOuPFQ{QDJizszN	MXvTRW5ITVJ?
MV-4-11	NFvy[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;D[YFKSzVyPUOuPFc6QTRizszN	NFe2TVNUSU6JRWK=
GAMG	NGfON2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rVSmlEPTB;Mz65NVMyPCEQvF2=	MmTSV2FPT0WU
KNS-62	NIDyeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkW0TWM2OD1\|Lkm0O\|MyKM7:TR?=	MnrLV2FPT0WU
MC116	NWfyfXdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvJTWM2OD1\|Lkm1OFg6KM7:TR?=	MXrTRW5ITVJ?
647-V	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmniTWM2OD1\|Lkm4OFUzKM7:TR?=	M1rCRXNCVkeHUh?=
U-87-MG	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTRwMUC0PFEh\|ryP	NIX0Z2NUSU6JRWK=
RPMI-8226	M4Pp[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHjWnkzUUN3ME20MlEyPjNzIN88US=>	NUH2[mw5W0GQR1XS
SW1417	NILm[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37QO2lEPTB;ND6xNlE1PyEQvF2=	NGDIdYZUSU6JRWK=
LAMA-84	Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTRwMUewNkDPxE1?	NFzrXFJUSU6JRWK=
LS-513	M2XaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7BTWM2OD12LkOxNlE4KM7:TR?=	M{PSbXNCVkeHUh?=
KLE	NYq4WZpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mke0TWM2OD12LkSwPFE6KM7:TR?=	MVTTRW5ITVJ?
HCT-116	NF;QWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEO4b41KSzVyPUSuOFExODdizszN	M2HDPXNCVkeHUh?=
EPLC-272H	NEHLXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTUWGRKSzVyPUSuOFE2OzNizszN	MkLuV2FPT0WU
KS-1	Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTkUHI4UUN3ME20MlUxQDh7IN88US=>	NG[2d\|RUSU6JRWK=
HT-1197	M3fVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTRwNUK2Olkh\|ryP	NXPublZKW0GQR1XS
LCLC-97TM1	MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\uOoJ2UUN3ME20MlU{Pjh4IN88US=>	NH2wZmZUSU6JRWK=
ES5	NUTuNpdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonUTWM2OD12LkizO\|I{KM7:TR?=	M4XVZnNCVkeHUh?=
CTB-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3OxXWlEPTB;ND64OFg5KM7:TR?=	MULTRW5ITVJ?
HL-60	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTRwOE[2NVEh\|ryP	MnH6V2FPT0WU
VM-CUB-1	NFnleHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DVNGlEPTB;ND64OlgyQSEQvF2=	MX;TRW5ITVJ?
MEG-01	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvvTWM2OD12Lkm5OFA{KM7:TR?=	MX;TRW5ITVJ?
KYSE-520	NIGzcXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4r2e2lEPTB;NT6yNFg{QSEQvF2=	MXnTRW5ITVJ?
HuO-3N1	M2HVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTVwMkSwOFMh\|ryP	M4DrU3NCVkeHUh?=
SW620	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPldVJKSzVyPUWuNlQ6PjRizszN	MX3TRW5ITVJ?
U031	MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHvTWM2OD13LkK1OFI1KM7:TR?=	NGrOfmFUSU6JRWK=
TE-5	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLweWRKSzVyPUWuOFA5PSEQvF2=	MUTTRW5ITVJ?
NCI-H747	MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHSV49sUUN3ME21MlQzPDd{IN88US=>	NHS0dotUSU6JRWK=
MG-63	NXTEOZFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfyV\|dKSzVyPUWuOFg4PjJizszN	NVjSW2NPW0GQR1XS
HC-1	NV[zeIZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTVwNUG4N\|kh\|ryP	M{PtSnNCVkeHUh?=
HCC2998	M3nhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTVwNUK2NVUh\|ryP	MmTEV2FPT0WU
NTERA-S-cl-D1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7v[45ZUUN3ME21MlU1PTN5IN88US=>	NHjK[mxUSU6JRWK=
KINGS-1	NFzsNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrzfJhKSzVyPUWuOlA6PDRizszN	M{jCTHNCVkeHUh?=
D-423MG	M4D1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTVwNkG3NFUh\|ryP	M3THVnNCVkeHUh?=
SW962	NYnMVlViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljkTWM2OD13Lk[yNFMzKM7:TR?=	M1v6OnNCVkeHUh?=
LOXIMVI	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTWeHpKSzVyPUWuOlM5PzNizszN	MWDTRW5ITVJ?
LS-411N	M1W2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTVwN{m0OFEh\|ryP	NYXGW4VuW0GQR1XS
NCI-H2291	MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rBcmlEPTB;NT65PFk1OyEQvF2=	MmLBV2FPT0WU
A549	M1zYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPDZ41KSzVyPU[uNVI2PTNizszN	NV61OpVrW0GQR1XS
LS-1034	MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTZwMkC3NFYh\|ryP	MYDTRW5ITVJ?
NB14	NULlZ5BJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTZwNEO4N\|Yh\|ryP	MUfTRW5ITVJ?
NCI-H1299	NGH6SZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPselFKSzVyPU[uOlMyPzFizszN	M4jxZ3NCVkeHUh?=
BT-549	M4nZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XEVWlEPTB;Nj62Olg5QSEQvF2=	NGnNRotUSU6JRWK=
J-RT3-T3-5	NWfZSGtrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljOTWM2OD14Lki2PUDPxE1?	MX7TRW5ITVJ?
SW756	MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlK0TWM2OD14LkmxNVc3KM7:TR?=	MX\TRW5ITVJ?
DJM-1	NXPBdIR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\WWXZKSzVyPU[uPVIxOTJizszN	NWLuUo9QW0GQR1XS
GP5d	M1PYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnaTWM2OD14Lkm3N\|k1KM7:TR?=	NV6xVYk6W0GQR1XS
MOLT-4	NUPDOFBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{n0fGlEPTB;Nz6wNlE{PSEQvF2=	NHj4fGRUSU6JRWK=
NCI-H28	NVe3XXRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTdwMU[0NFUh\|ryP	MnrKV2FPT0WU
MN-60	M3vjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjXTWM2OD15LkK4NFg6KM7:TR?=	MUjTRW5ITVJ?
RMG-I	NFPnPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWroVldsUUN3ME23MlM6Ojl4IN88US=>	MoXrV2FPT0WU
COLO-800	NITwcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7HS4dKSzVyPUeuOFE1PDZizszN	NHzHeVdUSU6JRWK=
DB	NFzqT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHvUXVKSzVyPUeuOlExODVizszN	NVrpfIFUW0GQR1XS
Ca-Ski	NWnYWJNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfzfIlKSzVyPUeuOlQzPTlizszN	MVjTRW5ITVJ?
HEL	MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTdwN{GyNFMh\|ryP	M3\iZ3NCVkeHUh?=
NH-12	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHITWM2OD15LkeyPFA5KM7:TR?=	M4mxfXNCVkeHUh?=
LB373-MEL-D	M13r[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTpRVNKSzVyPUeuO\|Y4PzFizszN	Ml30V2FPT0WU
SW900	M3\nWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfKTWM2OD15LkiyNVIyKM7:TR?=	NYfyXm1DW0GQR1XS
JVM-3	M1TFXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEG1VWVKSzVyPUeuPFk2QTlizszN	NHrV[YpUSU6JRWK=
OAW-28	M3PjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTdwOUS1O\|gh\|ryP	NH2z[JJUSU6JRWK=
KURAMOCHI	NXv3eZpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MortTWM2OD15Lkm0PFEyKM7:TR?=	M2XiXHNCVkeHUh?=
BE-13	M3uxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTdwOUixNVIh\|ryP	M2myOXNCVkeHUh?=
VMRC-RCZ	M3Hm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknETWM2OD16LkCxOlk4KM7:TR?=	NVfCTXZDW0GQR1XS
NCI-H727	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLrNHpJUUN3ME24MlExPDJizszN	M3;GfXNCVkeHUh?=
SW1710	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfzbJhYUUN3ME24MlE5PTF3IN88US=>	NXLMcXRUW0GQR1XS
D-502MG	NFzSVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4n3WmlEPTB;OD6yPVI5OiEQvF2=	NIHBfo1USU6JRWK=
NCI-H1993	NWTjbZV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRThwM{O2N\|Eh\|ryP	M{LXRnNCVkeHUh?=
SCC-4	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX[zfFNqUUN3ME24MlQ1ODV7IN88US=>	M3PidHNCVkeHUh?=
HAL-01	NEjnNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{OzfWlEPTB;OD61NVkyKM7:TR?=	MnrFV2FPT0WU
GT3TKB	M1jBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\GemlEPTB;OD62O\|k3PCEQvF2=	M2TSZnNCVkeHUh?=
SK-OV-3	NHXK[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRThwN{GzNlkh\|ryP	NGe3fI9USU6JRWK=
COLO-829	NIDsOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLmTWM2OD16LkiwPVc3KM7:TR?=	MlnsV2FPT0WU
OCI-AML2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVf4VVN5UUN3ME24Mlk2PDhzIN88US=>	MVfTRW5ITVJ?
OS-RC-2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\1dmlEPTB;OT6wNlE6KM7:TR?=	M4TpfHNCVkeHUh?=
BFTC-909	NUS5XJlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTlwME[3PVkh\|ryP	NYHnS2szW0GQR1XS
EW-11	NFWwRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTlwMUe2OVMh\|ryP	NFj0OnFUSU6JRWK=
HCE-4	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXn[5BNUUN3ME25MlIyPTV6IN88US=>	NX7s[XdoW0GQR1XS
BALL-1	MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTlwMkG5NFch\|ryP	MY\TRW5ITVJ?
SF539	M4GzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTlwMkO1OlIh\|ryP	MXrTRW5ITVJ?
CAMA-1	MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DRXWlEPTB;OT6yPFEzQCEQvF2=	NX\pO28{W0GQR1XS
C32	NILGUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjBWndzUUN3ME25MlM{ODZ2IN88US=>	M32zZXNCVkeHUh?=
NCI-H1703	NGju[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTlwM{SzO\|Uh\|ryP	MofzV2FPT0WU
NCI-H1650	NV3McJpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3lTmViUUN3ME25MlYxQTR4IN88US=>	MWrTRW5ITVJ?
NCI-H1563	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PvbWlEPTB;OT63OlA{OSEQvF2=	NITiRnpUSU6JRWK=
CAL-85-1	M3uzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTlwOEezPFMh\|ryP	NFnS[IpUSU6JRWK=
UM-UC-3	NUnibWt1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTlwOUWwN{DPxE1?	M2HBcXNCVkeHUh?=
BxPC-3	NF3DdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHn0TVlKSzVyPUGwMlA6PzJizszN	MYTTRW5ITVJ?
MHH-PREB-1	M2HwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTFyLkG5PVkh\|ryP	MWnTRW5ITVJ?
DEL	MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfhTWM2OD1zMD6zPVQ3KM7:TR?=	NGK2dFFUSU6JRWK=
HuCCT1	NIT3OJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYP5UFJtUUN3ME2xNE43ODN\|IN88US=>	MVnTRW5ITVJ?
OVCAR-4	MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFj6fnFKSzVyPUGwMlg5OzVizszN	NXHTfmJwW0GQR1XS
CAL-72	NWTrbW5RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3FVYZ[UUN3ME2xNE46OzlzIN88US=>	NHz2VlRUSU6JRWK=
HCC1954	NGjjVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HyVWlEPTB;MUGuNFc2PCEQvF2=	MnXQV2FPT0WU
EFO-21	NXP4NnhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTFzLkGwOFUh\|ryP	NXrMS\|dNW0GQR1XS
FTC-133	M3vUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nBXGlEPTB;MUGuNVQxPyEQvF2=	MkG1V2FPT0WU
SK-MEL-24	MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFe0dXNKSzVyPUGxMlI{PjZizszN	NEPPcWZUSU6JRWK=
UACC-62	M1;xcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW[0Nm95UUN3ME2xNU4zOzZ6IN88US=>	NH;NOHRUSU6JRWK=
NCI-H650	NYH3OYI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1r3SWlEPTB;MUGuNlQyQCEQvF2=	M{PM[HNCVkeHUh?=
ALL-PO	NXPSTpY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTpTWM2OD1zMT6yOVEzKM7:TR?=	M3T6dnNCVkeHUh?=
T84	NX7wWpY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTFzLkO5NFch\|ryP	NUfEbZZOW0GQR1XS
IST-MEL1	NWjsc2ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTFzLkS1OVkh\|ryP	Mn;rV2FPT0WU
SW626	MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrFcolKSzVyPUGxMlU4PTVizszN	NYnPfYdtW0GQR1XS
RPMI-2650	MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGL2dI5KSzVyPUGxMlU5QDVizszN	NI\WXVZUSU6JRWK=
MC-IXC	NXjhem1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTFzLk[3Nlgh\|ryP	MV3TRW5ITVJ?
HOP-62	NYL5eWVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zRfWlEPTB;MUGuOlc3PCEQvF2=	NI\SZXFUSU6JRWK=
NOS-1	NVizbZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{j0c2lEPTB;MUGuO\|ExQSEQvF2=	NUf3W5JlW0GQR1XS
SW1573	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTBUXNKUUN3ME2xNU44Ojl3IN88US=>	NYPCe41qW0GQR1XS
WM-115	MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\uTWM2OD1zMT63OVg5KM7:TR?=	MVrTRW5ITVJ?
HuO9	Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHTTWM2OD1zMT64O\|c1KM7:TR?=	M4HRb3NCVkeHUh?=
YAPC	M37hSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTSUVdIUUN3ME2xNU46OjV7IN88US=>	NHq3T\|RUSU6JRWK=
MDA-MB-453	NHTSbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4T1XGlEPTB;MUGuPVUyPSEQvF2=	NFTlXmdUSU6JRWK=
NCI-H596	NYizSnQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWm2ZVVqUUN3ME2xNk4xOzZ7IN88US=>	NXT0ZppJW0GQR1XS
A172	MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTqR5hKUUN3ME2xNk4xPzl6IN88US=>	NEj1[o1USU6JRWK=
RS4-11	NEPnZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTF{LkG3NlUh\|ryP	M2jhPXNCVkeHUh?=
HCC1937	NFGzOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4P6S2lEPTB;MUKuO\|U3PCEQvF2=	NYLYWYFyW0GQR1XS
SW837	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF:4NHpKSzVyPUGyMlkxOjhizszN	M4LVWnNCVkeHUh?=
NMC-G1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTF{LkmyN\|Qh\|ryP	MlnwV2FPT0WU
PFSK-1	M375SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnjTWtKSzVyPUGzMlA3KM7:TR?=	M{ex[3NCVkeHUh?=
DBTRG-05MG	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnNTWM2OD1zMz6wOlMzKM7:TR?=	NGP6[\|JUSU6JRWK=
SK-UT-1	NUHnTYo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGe4e3NKSzVyPUGzMlExQDNizszN	NFXueolUSU6JRWK=
OVCAR-5	M1nZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXX6TldGUUN3ME2xN{4yPTl\|IN88US=>	NYrQUINmW0GQR1XS
8505C	M2fQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLjTWM2OD1zMz6yNFY4KM7:TR?=	M2\MRXNCVkeHUh?=
SK-MEL-1	M1T1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnXd2tKSzVyPUGzMlcyOzVizszN	NVu5b5lyW0GQR1XS
LK-2	NFfNcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXWy[JAxUUN3ME2xN{44PjN7IN88US=>	MoDIV2FPT0WU
OE33	NVzxW24zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPNTWM2OD1zMz63PFYh\|ryP	NI\6VnVUSU6JRWK=
Ramos-2G6-4C10	M4f1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTF2LkCyNFIh\|ryP	NUnTPJdVW0GQR1XS
EW-13	M2jhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknVTWM2OD1zND6wN\|UzKM7:TR?=	M3OzZ3NCVkeHUh?=
NCI-H1793	MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXjN4hKSzVyPUG0MlIxQDdizszN	NVTxS4NQW0GQR1XS
BHT-101	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjHSmpPUUN3ME2xOE4zPDFizszN	NFPhVolUSU6JRWK=
RKO	NELjXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnO3TWM2OD1zND61NFc2KM7:TR?=	NW\6[\|NnW0GQR1XS
NEC8	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYS5[JQ3UUN3ME2xOE42PDd{IN88US=>	MY\TRW5ITVJ?
PANC-10-05	NXzVXFloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4q3OWlEPTB;MUSuOlI1PyEQvF2=	MWfTRW5ITVJ?
NCI-H2030	MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2racWlEPTB;MUSuOlQ1QCEQvF2=	NHnkSm9USU6JRWK=
C2BBe1	NXfvXXY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI[4bIRKSzVyPUG0Mlc3PCEQvF2=	NWjsSWJMW0GQR1XS
EM-2	M13PNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo[wTWM2OD1zND64OVc3KM7:TR?=	MVTTRW5ITVJ?
HCC1395	NHP4SndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mni4TWM2OD1zND65N\|M5KM7:TR?=	NHLTNnlUSU6JRWK=
A2058	MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHRVYVKSzVyPUG1MlA1ODlizszN	NEnKfnZUSU6JRWK=
SW1463	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rVfWlEPTB;MUWuNFQ5PSEQvF2=	MYrTRW5ITVJ?
J82	NH7G[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHFOZpKSzVyPUG1MlA2PyEQvF2=	MVvTRW5ITVJ?
CAL-120	M1r3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\kPWlEPTB;MUWuNVQ1PyEQvF2=	NYLUeIpvW0GQR1XS
COLO-824	NUTUUI1[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moi5TWM2OD1zNT6xOVc6KM7:TR?=	Mn3GV2FPT0WU
LNCaP-Clone-FGC	NEPrcm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7yTWM2OD1zNT60NlQ5KM7:TR?=	M2j5[3NCVkeHUh?=
CP66-MEL	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVe2emhsUUN3ME2xOU41Pjh6IN88US=>	NYLROo9WW0GQR1XS
OC-314	NGPwWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrlTWM2OD1zNT60O\|E1KM7:TR?=	M4\wfnNCVkeHUh?=
OVCAR-8	M2jyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LI[WlEPTB;MUWuPFg3OSEQvF2=	MoDZV2FPT0WU
MFE-280	NWjZdoN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTF4LkC0PFgh\|ryP	NHnxdFJUSU6JRWK=
MHH-NB-11	NUW0WVA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLXTWM2OD1zNj6wPFM6KM7:TR?=	NIjobppUSU6JRWK=
SW1990	M2L6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPsVotKSzVyPUG2MlE4PTVizszN	M4LCdnNCVkeHUh?=
U-266	NVXtU5VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTF4LkKyPVkh\|ryP	M3K5NnNCVkeHUh?=
MFM-223	NFyzcIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HOPGlEPTB;MU[uN\|k3PSEQvF2=	MnrMV2FPT0WU
L-363	M3v2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPRUFZKSzVyPUG2MlQ2PzdizszN	MW\TRW5ITVJ?
MCF7	NHHu[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vVPWlEPTB;MU[uOFczOyEQvF2=	M2f2TnNCVkeHUh?=
SK-MEL-3	MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PZTGlEPTB;MU[uOFc5PyEQvF2=	Ml7WV2FPT0WU
HH	M2exO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHPfWJ{UUN3ME2xOk42OTZ{IN88US=>	NIn0VnhUSU6JRWK=
no-10	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4OxT2lEPTB;MU[uOlM1OyEQvF2=	NHW2NmlUSU6JRWK=
HuP-T3	NXrve3VkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTF4Lk[1O\|Yh\|ryP	MnvOV2FPT0WU
QIMR-WIL	MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\aTWM2OD1zNj63NVA2KM7:TR?=	NWK1WnRiW0GQR1XS
NCI-H1092	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIP4fHVKSzVyPUG2Mlg{OTZizszN	MUPTRW5ITVJ?
MZ2-MEL	Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTF4Lki0NFMh\|ryP	MYXTRW5ITVJ?
ES3	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTF4LkmxN\|Qh\|ryP	NUDC[o82W0GQR1XS
COLO-684	NFT5V2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn2zTWM2OD1zNj65OFc4KM7:TR?=	NUn6WXM3W0GQR1XS
NCI-H661	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfGXIxiUUN3ME2xOk46Pjl2IN88US=>	MULTRW5ITVJ?
CP50-MEL-B	NF[0bnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIX1Z4dKSzVyPUG3MlA{PDNizszN	MlexV2FPT0WU
NCI-H2405	NVXPT3hQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXyTWM2OD1zNz6xPVc1KM7:TR?=	NVTRd2NPW0GQR1XS
U-2-OS	NU\ufnk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHG4e5VKSzVyPUG3MlU{ODdizszN	NHnWRnZUSU6JRWK=
RERF-LC-MS	M2qyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUeyVm1QUUN3ME2xO{42PTB6IN88US=>	MkTUV2FPT0WU
NCI-H2342	Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zE[2lEPTB;MUeuOVU4KM7:TR?=	Mlf4V2FPT0WU
ES8	NX30XXQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTF5Lk[wPFch\|ryP	MojYV2FPT0WU
MOLT-16	NWnFUGNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml:zTWM2OD1zNz64PVM1KM7:TR?=	MVXTRW5ITVJ?
RH-18	M{fuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHn4SpRKSzVyPUG4MlAxOzVizszN	NHjZR5ZUSU6JRWK=
D-283MED	NFnROZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TqWWlEPTB;MUiuNFA5QCEQvF2=	M2TFNnNCVkeHUh?=
RCC10RGB	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jMOWlEPTB;MUiuNFU2QSEQvF2=	MX;TRW5ITVJ?
NCI-H1437	NI\ZS\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPvTWM2OD1zOD6xOlQyKM7:TR?=	NUjjTJFrW0GQR1XS
SW982	M3O3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXSTVdJUUN3ME2xPE4zPjdzIN88US=>	MkjWV2FPT0WU
IST-MES1	Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTF6LkS0Nlgh\|ryP	MoLyV2FPT0WU
A704	MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3Tk[mlEPTB;MUiuOFc2OyEQvF2=	NIXIe\|hUSU6JRWK=
ESS-1	NXK0d5VnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWGxRZFFUUN3ME2xPE42OjB3IN88US=>	MlqwV2FPT0WU
SCH	NV;PXYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLX[YIyUUN3ME2xPE43PDV4IN88US=>	M1HyOnNCVkeHUh?=
COLO-320-HSR	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTF6Lke0OkDPxE1?	M1\OU3NCVkeHUh?=
Mo-T	M2rZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTBeFBnUUN3ME2xPE45OjB2IN88US=>	NXe1TpVmW0GQR1XS
Saos-2	M1vFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTF7LkGxOlIh\|ryP	NX7uWlk5W0GQR1XS
SW684	Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4GyNGlEPTB;MUmuNVMzPiEQvF2=	MoPXV2FPT0WU
KMOE-2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVGwTHpPUUN3ME2xPU4zOjR{IN88US=>	NXLjboZrW0GQR1XS
MMAC-SF	Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3X5RWlEPTB;MUmuNlYxPyEQvF2=	M3fTZXNCVkeHUh?=
JAR	NEWxRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\yRlNKSzVyPUG5MlI6QSEQvF2=	MUTTRW5ITVJ?
SK-MEL-28	M2rUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HaVGlEPTB;MUmuN\|M3OyEQvF2=	Mk\QV2FPT0WU
KNS-81-FD	MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\vO2RYUUN3ME2xPU42PDZ6IN88US=>	MoPtV2FPT0WU
ES7	M16xfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXqxVIFjUUN3ME2xPU43Ojl{IN88US=>	MoLVV2FPT0WU
AsPC-1	M2e5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;VTWM2OD1zOT62OFcyKM7:TR?=	NXzTNnJiW0GQR1XS
NCI-H1155	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzoZ25DUUN3ME2xPU44OjN6IN88US=>	M1jYdXNCVkeHUh?=
KYSE-510	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTF7Lki3OFgh\|ryP	NWD4XJE{W0GQR1XS
ES1	Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\jfZZKSzVyPUG5MlkzOTNizszN	NVzpSGQzW0GQR1XS
PC-3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFi2WlhKSzVyPUG5Mlk3ODRizszN	M3rldnNCVkeHUh?=
GCT	NF\1UnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTJyLkOwNlYh\|ryP	MXPTRW5ITVJ?
KARPAS-299	M{H5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DX[2lEPTB;MkCuN\|QzOiEQvF2=	NH\jVpRUSU6JRWK=
DOHH-2	NVTnVYllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDHcFJzUUN3ME2yNE42PDZ\|IN88US=>	MYfTRW5ITVJ?
COLO-741	M3TWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTJyLk[2JO69VQ>?	MnLwV2FPT0WU
NCI-H1395	NXXsXGt3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHLXGNLUUN3ME2yNE43Pjl5IN88US=>	MmTHV2FPT0WU
HCC1187	NHLyVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXsPJlKSzVyPUKwMlY4OzRizszN	M1jYWnNCVkeHUh?=
Becker	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTJyLkeyNFEh\|ryP	NUPpfZcyW0GQR1XS
LU-134-A	NHXK[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvETWM2OD1{MT6xNFI3KM7:TR?=	MmHYV2FPT0WU
MKN45	MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLrTWM2OD1{MT6xOVUyKM7:TR?=	NHnBTWtUSU6JRWK=
LC-2-ad	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\Zb2lEPTB;MkGuNlczQSEQvF2=	MWTTRW5ITVJ?
EW-24	MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3K3UmlEPTB;MkGuN\|k1PSEQvF2=	Mom1V2FPT0WU
SK-N-AS	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTJzLkiyO\|Yh\|ryP	NU\EZYhkW0GQR1XS
NCI-H2052	NX;1XoJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;qTJVuUUN3ME2yNU45QTZ\|IN88US=>	MWTTRW5ITVJ?
A4-Fuk	NUfn[VdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTJ{LkG0NVkh\|ryP	MorHV2FPT0WU
NB10	Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoKwTWM2OD1{Mj6yN\|cyKM7:TR?=	NVrzbmNKW0GQR1XS
CHP-212	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFn2UWtKSzVyPUKyMlMzOjJizszN	MmT3V2FPT0WU
KM12	M{TDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTvTWM2OD1{Mj6zOVYh\|ryP	NVvIbnJiW0GQR1XS
JEG-3	M1S0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTJ{LkO3PEDPxE1?	MYLTRW5ITVJ?
LN-405	Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF36W2hKSzVyPUKyMlU6OTNizszN	Mmr6V2FPT0WU
HCT-15	NH\lT\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXmNIFKSzVyPUKyMlc1PDFizszN	MlXHV2FPT0WU
MLMA	MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;lTWM2OD1{Mj63OFch\|ryP	Mn;ZV2FPT0WU
GI-1	M4fHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnS1TWM2OD1{Mj63OlU5KM7:TR?=	M13P[3NCVkeHUh?=
RT-112	NV7rNJlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmW1TWM2OD1{Mj64OlE3KM7:TR?=	NEfEe3JUSU6JRWK=
MPP-89	NFvXSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTJ{Lki2OlEh\|ryP	MWnTRW5ITVJ?
A3-KAW	NVLuVYYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\pWmlEPTB;MkOuNVAxOyEQvF2=	NXvaclBkW0GQR1XS
KALS-1	NWDzc29[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHX4enJKSzVyPUKzMlE1OTRizszN	NFrIWmtUSU6JRWK=
SF126	MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nkbWlEPTB;MkOuOlkzPCEQvF2=	MVHTRW5ITVJ?
SiHa	NF7wdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PtNmlEPTB;MkOuPVMzPyEQvF2=	MXrTRW5ITVJ?
MDA-MB-415	MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWW1blREUUN3ME2yN{46PDl7IN88US=>	NYPucWx7W0GQR1XS
Daoy	M4nPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInBZlFKSzVyPUK0MlEzPiEQvF2=	M{TWeXNCVkeHUh?=
COR-L23	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGq2cGtKSzVyPUK0MlE4PjdizszN	NUT1S3NVW0GQR1XS
KG-1	NXfwbVB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3kcFBbUUN3ME2yOE4yQTJ6IN88US=>	M3\QbXNCVkeHUh?=
L-428	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTJ2LkW3PVEh\|ryP	NFjRTFdUSU6JRWK=
NCI-H520	NVLrPItIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPtbHd2UUN3ME2yOE45QDZzIN88US=>	NWXlbpFzW0GQR1XS
COLO-792	M4L3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTJ3LkK3N\|Ih\|ryP	NH3KS3NUSU6JRWK=
NB12	MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXGR5BYUUN3ME2yOU4zQTR5IN88US=>	M2TuUHNCVkeHUh?=
GAK	NIrKeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2e3UGlEPTB;MkWuNlk3OyEQvF2=	M2TKTnNCVkeHUh?=
SW780	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTJ3LkOyOlQh\|ryP	NF3XNGJUSU6JRWK=
GB-1	NWTsVWtUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnftTWM2OD1{NT60NFY6KM7:TR?=	NYDCb4R3W0GQR1XS
P12-ICHIKAWA	NGrDe\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknkTWM2OD1{NT60O\|g2KM7:TR?=	NHftN3VUSU6JRWK=
NCI-H1651	M3;0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrjRVlXUUN3ME2yOU42QTdizszN	M3zO[HNCVkeHUh?=
KE-37	MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrzTWM2OD1{NT63N\|E2KM7:TR?=	MXvTRW5ITVJ?
CCRF-CEM	NHGyblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTJ3Lkm2O{DPxE1?	MUjTRW5ITVJ?
SF295	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1e2RWlEPTB;Mk[uNFQzPSEQvF2=	NWq5fmFmW0GQR1XS
G-361	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f3OmlEPTB;Mk[uNVAzPyEQvF2=	NX\2e2lsW0GQR1XS
HOP-92	NVfrdpdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTJ4LkGyNlYh\|ryP	MUjTRW5ITVJ?
UMC-11	MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTJ4LkS1NVQh\|ryP	MWXTRW5ITVJ?
IST-SL1	NEfZ[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrWTWM2OD1{Nj62OVkyKM7:TR?=	Mon1V2FPT0WU
TE-11	M1XhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIT1W3RKSzVyPUK2Mlc4PTJizszN	NHv0N29USU6JRWK=
NCI-H1304	NF[1TlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTJ4LkmxNFgh\|ryP	NEjDd41USU6JRWK=
SJSA-1	NWDORWpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfsRnE5UUN3ME2yO{4xOTd4IN88US=>	NXeyUnc4W0GQR1XS
BCPAP	MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV2wWJZiUUN3ME2yO{4yOzdizszN	Mn:xV2FPT0WU
HTC-C3	NW\ZXYp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\1TWM2OD1{Nz6yOVYyKM7:TR?=	MljYV2FPT0WU
EW-16	M1Oxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PtS2lEPTB;MkeuNlk1PyEQvF2=	NIi5cYFUSU6JRWK=
HT-144	NIrTUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTJ5LkSwN\|Ih\|ryP	NWDEblN3W0GQR1XS
MHH-ES-1	NUHuOnl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXnTWM2OD1{Nz60OFQ4KM7:TR?=	NXvnOXhoW0GQR1XS
T98G	NHTsbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXn1VZRxUUN3ME2yO{42QDR4IN88US=>	NIDEWXBUSU6JRWK=
RPMI-8866	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTJ5Lke1OlIh\|ryP	MoLGV2FPT0WU
BEN	M4\zT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HUdGlEPTB;MkeuPFUyPyEQvF2=	MkOyV2FPT0WU
MDA-MB-231	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DWbGlEPTB;MkiuNlc6PSEQvF2=	MWPTRW5ITVJ?
HuH-7	MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofITWM2OD1{OD60NFI5KM7:TR?=	MkXrV2FPT0WU
SK-N-FI	MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLINZBKSzVyPUK4MlQ{OyEQvF2=	M{TFVHNCVkeHUh?=
AN3-CA	MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVezT\|BxUUN3ME2yPE41Ozl3IN88US=>	M4rZVnNCVkeHUh?=
EGI-1	NH;jVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkm5TWM2OD1{OD61PVI5KM7:TR?=	NYO3[28xW0GQR1XS
697	M3P0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHwZnQ4UUN3ME2yPE43OzNzIN88US=>	M37pO3NCVkeHUh?=
TCCSUP	NXjFdZhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlH5TWM2OD1{OD62OFE5KM7:TR?=	NVW3fnVzW0GQR1XS
GR-ST	NFXRSWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPKW2ZHUUN3ME2yPE43Pjl4IN88US=>	MknxV2FPT0WU
SK-N-DZ	M4K3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfmWXFKSzVyPUK4MlY5QDVizszN	MXjTRW5ITVJ?
MIA-PaCa-2	M{njfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mli2TWM2OD1{OD63PVU6KM7:TR?=	MW\TRW5ITVJ?
IGR-1	NVnzZ2NHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTJ6Lki4O\|Qh\|ryP	M2G5dXNCVkeHUh?=
BFTC-905	NX60NZMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;JWoR1UUN3ME2yPU4zPzB3IN88US=>	MYPTRW5ITVJ?
NCI-H1581	MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nKdWlEPTB;MkmuN\|E1PSEQvF2=	MlPYV2FPT0WU
RD	Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjYNIpNUUN3ME2yPU42OjN\|IN88US=>	NX70VGFNW0GQR1XS
SF268	MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGS0OZhKSzVyPUK5MlU6OzFizszN	M{TsVnNCVkeHUh?=
SHP-77	NI[ydZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPBTWM2OD1{OT62NVgzKM7:TR?=	M3TldnNCVkeHUh?=
D-566MG	NUK5XFB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU[0Z4x6UUN3ME2yPU46Ozl\|IN88US=>	MVTTRW5ITVJ?
TGBC1TKB	NUT2XnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\KPWlEPTB;M{CuNVI{QCEQvF2=	NH6zRVZUSU6JRWK=
MEL-HO	M4K3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjpXohxUUN3ME2zNE4yPDJ\|IN88US=>	M3OxbHNCVkeHUh?=
SJRH30	MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3m1O2lEPTB;M{CuNlExQCEQvF2=	MUnTRW5ITVJ?
D-336MG	MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX32dW5iUUN3ME2zNE4zQDl{IN88US=>	MVTTRW5ITVJ?
C3A	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjmdIhKSzVyPUOwMlI6OjdizszN	MXfTRW5ITVJ?
Calu-6	MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTNyLkK5OlMh\|ryP	NFmyfnlUSU6JRWK=
MZ1-PC	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjwTWM2OD1\|MD6zPVMh\|ryP	NY\XS5dFW0GQR1XS
KYSE-70	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTNyLkWxNVQh\|ryP	NHi4TGRUSU6JRWK=
CAPAN-1	NHjORXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTNyLkWxPFEh\|ryP	M{fSRnNCVkeHUh?=
DK-MG	NU\zUoRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnO2TWM2OD1\|MD61OFU3KM7:TR?=	M3;HR3NCVkeHUh?=
SK-HEP-1	NGniSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTNyLk[zNlYh\|ryP	M{\RXHNCVkeHUh?=
MS-1	NV\kNnlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDwdYpKSzVyPUOwMlg5QDlizszN	NUfuWnI2W0GQR1XS
GI-ME-N	NWfRPJVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;BeWVJUUN3ME2zNU4xPTdzIN88US=>	NITkPIpUSU6JRWK=
NCI-H510A	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLhOFdKSzVyPUOxMlQxODZizszN	MkTaV2FPT0WU
NB17	NHztVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\VTWM2OD1\|MT61NVg2KM7:TR?=	NHH0VIhUSU6JRWK=
639-V	NHHqe5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFGzZnNKSzVyPUOxMlUzPDNizszN	MXrTRW5ITVJ?
CAL-51	NI\RdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDmZVhKSzVyPUOxMlU3PjdizszN	NYKzbG5YW0GQR1XS
HGC-27	NULydFZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3BTWM2OD1\|MT61PFc{KM7:TR?=	MWTTRW5ITVJ?
GOTO	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTrTWM2OD1\|MT64OVA3KM7:TR?=	NFLhemdUSU6JRWK=
ChaGo-K-1	NXHDZZBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\HbWlEPTB;M{KuNFA4KM7:TR?=	NXGzd\|JtW0GQR1XS
RO82-W-1	M1Gy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTN{LkG2NFQh\|ryP	MoGzV2FPT0WU
SH-4	M1\CNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDCTWM2OD1\|Mj6xPFU5KM7:TR?=	MVPTRW5ITVJ?
A204	M332[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTN{LkWwOlkh\|ryP	M13CNHNCVkeHUh?=
DMS-273	NV7jWm5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfDTWM2OD1\|Mj61N\|IzKM7:TR?=	NYPEPVV5W0GQR1XS
KGN	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnLSmtFUUN3ME2zNk43OzNizszN	MV\TRW5ITVJ?
SK-MEL-2	M4\Nb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTN{Lk[1Nlch\|ryP	NFfO[ZJUSU6JRWK=
NCI-H2228	MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1n4bWlEPTB;M{KuOlYxOiEQvF2=	NFrl[45USU6JRWK=
MKN28	M3TpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1r4TGlEPTB;M{KuO\|g{QCEQvF2=	NFXXe3RUSU6JRWK=
H-EMC-SS	MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1[5e2lEPTB;M{KuPVY4QCEQvF2=	MW\TRW5ITVJ?
ATN-1	M4Sz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEGwbVdKSzVyPUOzMlE1OTZizszN	M3;FcXNCVkeHUh?=
D-263MG	NFnpNJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlu0TWM2OD1\|Mz64N\|c5KM7:TR?=	MYfTRW5ITVJ?
LU-135	Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjLcYNKSzVyPUOzMlg5OjlizszN	NHfsfGhUSU6JRWK=
C8166	M1XxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HWVGlEPTB;M{OuPFg2PCEQvF2=	NFzSc3VUSU6JRWK=
T-24	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{WwRmlEPTB;M{SuNFIxPSEQvF2=	Mkn1V2FPT0WU
Mewo	MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEn0SY1KSzVyPUO0MlE{PDlizszN	M2TITXNCVkeHUh?=
22RV1	M4LEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\SbW9KSzVyPUO0MlE4PTRizszN	MkDyV2FPT0WU
KM-H2	M{KzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTN2LkG3O\|kh\|ryP	NH\LeG5USU6JRWK=
NCI-H2122	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHr6RpZKSzVyPUO0MlM1PzFizszN	MXzTRW5ITVJ?
ABC-1	NWnZZ40xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4j4WmlEPTB;M{SuN\|Y6OyEQvF2=	NXfTNY5OW0GQR1XS
NCI-H1355	NYnFXnF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTN2LkO4PFkh\|ryP	NIr4PVBUSU6JRWK=
NOMO-1	M3PsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnoTWM2OD1\|ND61O\|A{KM7:TR?=	M2fNUnNCVkeHUh?=
MZ7-mel	NHqxcFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTN2Lk[0PFch\|ryP	MWTTRW5ITVJ?
NCI-H810	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{mx[2lEPTB;M{SuO\|I4QCEQvF2=	M3TCe3NCVkeHUh?=
D-392MG	NGe2SFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2H4NmlEPTB;M{WuNFU3PSEQvF2=	MUHTRW5ITVJ?
LB771-HNC	MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTN3LkG2OVgh\|ryP	M3HWbXNCVkeHUh?=
COLO-679	M1z0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2ToeGlEPTB;M{WuN\|g5KM7:TR?=	M1LaS3NCVkeHUh?=
SK-PN-DW	NXL1OXJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfhco5KSzVyPUO1MlQ{PjlizszN	NUHEOVlRW0GQR1XS
VA-ES-BJ	MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XnR2lEPTB;M{WuOFY1QSEQvF2=	MUjTRW5ITVJ?
KNS-42	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPCPGZCUUN3ME2zOU42QDJ4IN88US=>	M2LZV3NCVkeHUh?=
RVH-421	NIrCeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXQO4tKSzVyPUO1Mlc3PDVizszN	MkXaV2FPT0WU
P30-OHK	NGXUWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTN3Lki3OVIh\|ryP	M1yxdXNCVkeHUh?=
G-402	NEDCenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTN3Lkm4Olch\|ryP	MYHTRW5ITVJ?
S-117	NFLqbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTN4LkOwNFgh\|ryP	NGrSW\|hUSU6JRWK=
RXF393	Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvHXnVKSzVyPUO2MlM4QDVizszN	M3vYbnNCVkeHUh?=
LCLC-103H	MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPsVpRKSzVyPUO2Mlc5ODNizszN	NYnCbpBjW0GQR1XS
U-118-MG	MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTN4Lki4OFch\|ryP	MVvTRW5ITVJ?
8-MG-BA	NHrpUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTN4Lkm0PFMh\|ryP	NYrVR4R[W0GQR1XS
MFH-ino	NWDQXIJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTN5LkOzO\|Eh\|ryP	MnvrV2FPT0WU
NCI-H23	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrxTZdsUUN3ME2zO{41OTl4IN88US=>	NUjV[3lxW0GQR1XS
NCI-H446	MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWG0[I8xUUN3ME2zO{41QDZ{IN88US=>	MlfNV2FPT0WU
LU-99A	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlm3TWM2OD1\|Nz61O\|MyKM7:TR?=	MmfjV2FPT0WU
KP-N-YN	NUXqO5lZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrFZ2ZYUUN3ME2zO{43OTl3IN88US=>	MWjTRW5ITVJ?
SCC-9	M3[wemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTN5Lke4N\|gh\|ryP	MXnTRW5ITVJ?
EFM-19	M3PDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF:5bFlKSzVyPUO3Mlc6PjdizszN	MlfTV2FPT0WU
A427	M{nVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\ndWRKSzVyPUO3MlkyODdizszN	MUfTRW5ITVJ?
LB831-BLC	M{Htcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvyPI1KSzVyPUO4MlYxOzlizszN	NH;LTXNUSU6JRWK=
HOS	NGPoO\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWP2V4R1UUN3ME2zPU43Ojd\|IN88US=>	NEjjOHJUSU6JRWK=
LAN-6	M4DjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHkN3pKSzVyPUSwMlAyOTJizszN	MoLyV2FPT0WU
U251	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTRyLkSwOVQh\|ryP	MoXyV2FPT0WU
SNU-387	NUXvSnpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDBbFdKSzVyPUSwMlQ2PTNizszN	MlzuV2FPT0WU
DMS-79	NYn5R2RYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXKTWM2OD12MD61PFg6KM7:TR?=	NIDSU2RUSU6JRWK=
SK-LU-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrhOJVKSzVyPUSwMlY2PjhizszN	NFXSb4VUSU6JRWK=
HT	M1LBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWO1eFhPUUN3ME20NE43PjN7IN88US=>	MnLnV2FPT0WU
KP-N-YS	Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYr3[3ltUUN3ME20NE43PzZ6IN88US=>	NV\0V4pOW0GQR1XS
DMS-114	NHPN[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\pbmlEPTB;NECuPFM4PCEQvF2=	MoXJV2FPT0WU
HUTU-80	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7rWFF7UUN3ME20NU4xPTZ7IN88US=>	M2rJfXNCVkeHUh?=
ONS-76	MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DBPGlEPTB;NEGuOFcxQSEQvF2=	NYDpOINUW0GQR1XS
A673	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXkNZFvUUN3ME20NU42OTV5IN88US=>	MoLtV2FPT0WU
HPAF-II	NHr5O5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvGTWM2OD12MT62O\|A6KM7:TR?=	M37iZXNCVkeHUh?=
UACC-257	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIn3[JpKSzVyPUSxMlc{PjlizszN	MUnTRW5ITVJ?
EW-22	NHLCWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTRzLki2PVch\|ryP	NHTXbFJUSU6JRWK=
NCI-H1755	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\BTWM2OD12MT64O\|I2KM7:TR?=	MXHTRW5ITVJ?
KYSE-150	NG[0VW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTR{LkG3PFIh\|ryP	M2iy[XNCVkeHUh?=
CGTH-W-1	Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTR{LkS5OVUh\|ryP	M13Jb3NCVkeHUh?=
NB13	NXG5d3BJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrNcYdKSzVyPUSyMlYzOTdizszN	M4jvSnNCVkeHUh?=
SW872	NILCRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkH0TWM2OD12Mj62N\|MyKM7:TR?=	M13sWnNCVkeHUh?=
KP-4	M{LvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3iZowyUUN3ME20Nk45QDN{IN88US=>	MULTRW5ITVJ?
HCC38	MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHwc2lKSzVyPUSyMlk3OThizszN	M3W4U3NCVkeHUh?=
BB49-HNC	NEPMPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\JTGlEPTB;NEOuNlM2PiEQvF2=	MVfTRW5ITVJ?
CAL-62	MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjCN4JKSzVyPUSzMlQxOjhizszN	NGXhUo9USU6JRWK=
NCI-H2029	M4jzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3BTWM2OD12Mz61OVgyKM7:TR?=	M{iwbXNCVkeHUh?=
M14	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmKzTWM2OD12ND6xN\|MzKM7:TR?=	NYfqUo1{W0GQR1XS
COLO-680N	M2fZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3TbnI3UUN3ME20OE4{OzlizszN	NWnOU4JXW0GQR1XS
Hs-578-T	NHP2eWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTR3LkCyPVQh\|ryP	NVLLZmZFW0GQR1XS
MSTO-211H	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zzZmlEPTB;NEWuPVQ5OiEQvF2=	M4D4Z3NCVkeHUh?=
EW-1	NFXzOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPwTWM2OD12NT65Olg6KM7:TR?=	M2HSVHNCVkeHUh?=
SW948	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWr1fpBmUUN3ME20Ok41PDZ{IN88US=>	MnzSV2FPT0WU
NCI-H460	M3Py[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfIfVhKSzVyPUS2MlUzOyEQvF2=	M4XISnNCVkeHUh?=
CAS-1	MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFn0fIFKSzVyPUS2Mlc4ODFizszN	NGL4UI1USU6JRWK=
TGBC11TKB	NIrkNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml65TWM2OD12Nz6xO\|c4KM7:TR?=	MYHTRW5ITVJ?
HD-MY-Z	MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWP1ZohCUUN3ME20PE44QDZizszN	MmjtV2FPT0WU
NCI-H226	Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILIRYhKSzVyPUS5Mlc4QDVizszN	M132cXNCVkeHUh?=
PA-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\aZpg2UUN3ME20PU45OzN3IN88US=>	NIXMbHVUSU6JRWK=
LB2518-MEL	MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1Hw[mlEPTB;NEmuPFczOyEQvF2=	M3;2OnNCVkeHUh?=
A101D	NFHaV\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLITZQ4UUN3ME20PU46PDJ3IN88US=>	MV7TRW5ITVJ?
NCI-H2087	NWn1W3BST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;FeWlEPTB;NEmuPVY5OiEQvF2=	NXvtblBGW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	CIP2A / p-AKT / AKT / PARP; PubMed: 25537503 Oncotarget Time-dependent effects of afatinib on CIP2A, p-AKT and apoptosis-related proteins in the sensitive H358 and resistant H460 cells. Cells were exposed to 10 μM afatinib for up to 48 hours. Immunoblots were scanned and quantitated to determine the ratio of the level of CIP2A to actin. Data are mean ± SD. n = 3 for the different time intervals. p-EGFR / p-IGF1R / p-ERK / p-AKT; PubMed: 26052929 Mol Carcinog Effects of afatinib on EGFR and IGF1R Signaling Pathways. H1975 cells were treated with afatinib with various doses and cell lysates were subjected to Western blot analysis. Afatinib effectively inhibits p-EGFR and p-ERK while p-AKT was partially inhibited. IGF1R phosphorylation was increased upon afatinib treatment in H1975 cells. p-VEGFR2 / VEGFR2 / JAG1 / DLL4 / NICD1 ; PubMed: 28533486 Oncotarget HUVECs were cultured in the presence of Vatalanib (100 nM) or DBZ (10 nM) for 1 h and then treated for 15 min with rhgal-3 (37 nM) and cultured for additional 6 hrs. After this period, the total protein was isolated and the protein levels of galectin-3, NICD1, DLL4, JAG1, VEGFR2 and VEGFR2-p were assessed by Western blot. β-actin was used as a loading control.	25537503 26052929 28533486
Growth inhibition assay	Cell apoptosis; PubMed: 25537503 Oncotarget Dose-dependent effects of afatinib on apoptosis. Data are mean ± SD. n = 3 for each concentration. , p < 0.05, *, p < 0.01, vs. no afatinib. Cell viability; PubMed: 26515464 Oncotarget A. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion and L858R. The proportional cell viability is shown. B. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion+T790M and L858R+T790M. The proportional cell viability is shown. C. MTS assay for Ba/F3 cells harboring wild type EGFR. The proportional cell viability is shown. Erlotinib, afatinib, osimertinib, and rociletinib were used as EGFR-TKIs. Error bars indicate standard deviation.	25537503 26515464
Immunofluorescence	p65; PubMed: 26317651 Oncotarget Effects of different treatments on the nuclear translocation of the NF-κB subunit p65. A2780T cells were treated with 2.5 μM afatinib for 48 hours, or 10 μM PDTC for 2 hours. Subsequently, the NF-κB subunit p65 (red) was localized by immunofluorescence and a confocal microscopy. Nuclei were stained with DAPI (blue). Scale bar = 10 μM. vacuoles; PubMed: 29713246 Cancer Cell Int Autophagy activation upon treatment with Afatinib and Sorafenib was validated using immunofluorescence in order to visualize a creation of autophagosomes; ×60 magnification. DMSO treatment was used as control. Green—autophagy vacuoles; Blue—Hoechst, nuclear staining.	26317651 29713246

In vivo

Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase activity assays: The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.
Cell Research: ^[1]	- Collapse Cell lines: NSCLC cells Concentrations: 0-10 μM Incubation Time: 1 hour Method: 1 × 10⁴ NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 10⁴ cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Athymic NMRI-nu/nu female mice Dosages: 20 mg/kg Administration: Oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	97 mg/mL (199.61 mM)
	Ethanol	15 mg/mL (30.86 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Afatinib (BIBW2992) SDF

Molecular Weight	485.94
Formula	C₂₄H₂₅ClFN₅O₃
CAS No.	439081-18-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CN(C)C/C=C/C(=O)NC1=CC2=C(NC3=CC=C(F)C(=C3)Cl)N=CN=C2C=C1OC4CCOC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04206787	Not yet recruiting	Drug: Afatinib	Non-squamous Non-Small Cell Lung Cancer	Boehringer Ingelheim	May 6 2020	--
NCT04158947	Recruiting	Drug: Afatinib\|Drug: T-DM1	HER2-positive Breast Cancer\|Brain Metastases	xuexin he\|Second Affiliated Hospital School of Medicine Zhejiang University	May 10 2020	Phase 2
NCT03711422	Not yet recruiting	Drug: Afatinib	Non-small Cell Lung Cancer\|Leptomeningeal Disease\|Central Nervous System Metastases	National Cancer Centre Singapore	October 2018	Phase 1
NCT03083678	Recruiting	Drug: Afatinib	Chordoma	Leiden University Medical Center\|Chordoma Foundation\|Boehringer Ingelheim	June 21 2018	Phase 2
NCT03370770	Completed	Drug: Afatinib\|Drug: Osimertinib	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	December 28 2017	--
NCT02423525	Recruiting	Drug: Afatinib	Brain Cancer	Santosh Kesari\|Boehringer Ingelheim\|John Wayne Cancer Institute	December 2016	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.
Classic EGFR Inhibitor

WZ4002 : Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Related EGFR Products

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)